SciSparc (SPRC) Cash from Investing Activities (2016 - 2018)
SciSparc (SPRC) posted Cash from Investing Activities of $53000.0 for Q4 2018, up 103.24% sequentially from -$1.6 million in Q3 2018, and up 688.89% YoY from $6718.3 in Q4 2017.
SciSparc (SPRC) Cash from Investing Activities (2016 - 2018) Analysis & Trends
SciSparc has reported Cash from Investing Activities for 3 years, with the latest figure at $53000.0 in Q4 2018.
- Quarterly Cash from Investing Activities rose 688.89% year-over-year to $53000.0 in Q4 2018, while the trailing twelve-month figure through Dec 2018 was -$2.1 million (down 3850.94% YoY) and the FY2025 annual result came in at -$1.4 million, up 13.85% from the prior year.
- Cash from Investing Activities improved to $53000.0 in Q4 2018 per SPRC's latest filing, from -$1.6 million in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $53000.0 in Q4 2018 and troughed at -$1.6 million in Q3 2018.
- A 3-year average of -$268500.0 and a median of -$9000.0 in 2017 frame the typical range for Cash from Investing Activities.
- The widest YoY moves for Cash from Investing Activities: up 688.89% in 2018, down 5488.89% in 2018.
- Over 3 years, Cash from Investing Activities stood at -$1000.0 in 2016, then sank by 800.0% to -$9000.0 in 2017, then surged by 688.89% to $53000.0 in 2018.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered $53000.0, -$1.6 million, and -$503000.0 for Q4 2018, Q3 2018, and Q2 2018 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | SciSparc | 831,418.60 | 831,418.60 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 53,000.00 |
| Dec 31, 2018 | 53,000.00 |
| Sep 30, 2018 | -1.64 Mn |
| Sep 30, 2018 | -1.64 Mn |
| Jun 30, 2018 | -503,000.00 |
| Jun 30, 2018 | -503,000.00 |
| Mar 31, 2018 | -9,000.00 |
| Mar 31, 2018 | -9,000.00 |
| Dec 31, 2017 | -9,000.00 |
| Dec 31, 2017 | -9,000.00 |
| Sep 30, 2017 | -35,000.00 |
| Sep 30, 2017 | -35,000.00 |
| Jun 30, 2017 | -9,000.00 |
| Jun 30, 2017 | -9,000.00 |
| Sep 30, 2016 | -1,000.00 |
| Sep 30, 2016 | -1,000.00 |